Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZINC69391 is a small-molecule, specific inhibitor of the Ras-related C3 botulinum toxin substrate 1 (Rac1) GTPase. It acts by masking the Trp56 residue on the surface of Rac1, thereby disrupting its interaction with guanine nucleotide exchange factors (GEFs) such as Tiam1 and DOCK180. This blockade prevents Rac1 activation (reducing intracellular Rac1-GTP levels) and downregulates downstream signaling effectors like Pak1. ZINC69391 has demonstrated preclinical efficacy in inhibiting cell proliferation, migration, and invasion, as well as inducing cell cycle arrest and apoptosis in aggressive cancer models, including breast cancer and glioma. It has also shown in vivo antimetastatic activity by reducing lung colonization in experimental metastasis models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ZINC69391.